Corbus Pharmaceuticals Holdings, Inc. (CRBP) News

Corbus Pharmaceuticals Holdings, Inc. (CRBP): $1.79

0.04 (+2.00%)

POWR Rating

Component Grades













Add CRBP to Watchlist
Sign Up

Industry: Biotech


of 491

in industry

Filter CRBP News Items

CRBP News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

CRBP News Highlights

  • For CRBP, its 30 day story count is now at 4.
  • Over the past 25 days, the trend for CRBP's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about CRBP are MG, AL and DM.

Latest CRBP News From Around the Web

Below are the latest news stories about Corbus Pharmaceuticals Holdings Inc that investors may wish to consider to help them evaluate CRBP as an investment opportunity.

Corbus Pharmaceuticals Announces Completion of Enrollment in NIH-Sponsored Phase 2 Study of Lenabasum for Treatment of Systemic Lupus Erythematosus (SLE)

First study to explore potential benefit of a cannabinoid receptor type 2 agonist in SLEStudy sponsored and funded by the Nastional Institute of Allergy and Infectious Diseases through the Autoimmunity Centers of Excellence (ACE) Cooperative NetworkTopline data expected in the second half of 2021SLE is a serious autoimmune disease with multi-organ involvement and affects more than 200,000 Americans Norwood, MA, April 20, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced that the last participant was enrolled in a Phase 2 study of lenabasum for the treatment of systemic lupus erythematosus (SLE). The...

Yahoo | April 20, 2021

Corbus: Assessing If Lenabasum Can Finally Break Through

Photo by Andrew Brookes/Cultura via Getty ImagesWe wrote about Corbus Pharmaceuticals (NASDAQ:CRBP) back in January and stated that the recent unsuccessful Lenabasum phase 3 and phase 2 trials would not end up being a death sentence for the firm. Expectations were very high before the result which meant a soft...

Individual Trader on Seeking Alpha | April 15, 2021

Corbus Pharmaceuticals Reports Last Subject Visit in DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis

Topline data on schedule for Q2 2021Dermatomyositis is a rare and life-threatening autoimmune disease characterized by skin and muscle inflammation, and affects ~80,000 people in North America, EU, and JapanThere is a significant need for safer and more effective treatments in dermatomyositis because of limitations of current treatment options Norwood, MA, March 30, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced that the last subject completed the final visit in the double-blind, placebo-controlled part of the Company’s Phase 3 DETERMINE study of lenabasum for the treatment of dermatomyositis. Th...

Yahoo | March 30, 2021

Corbus Pharmaceuticals Holdings (CRBP) Investor Presentation - Slideshow

The following slide deck was published by Corbus Pharmaceuticals Holdings, Inc. in conjunction with this event....

SA Transcripts on Seeking Alpha | March 26, 2021

Cannabis Stock Gainers And Losers From March 19, 2021

GAINERS: SugarBud Craft Growers (PINK: RLLRF ) shares closed up 26.19% at $0.05 Cipher Pharms Inc (PINK: CPHRF ) shares closed up 17.11% at $0.89 Chemesis International (PINK: CADMF ) shares closed up 16.82% at $0.71 CANADA HOUSE WELLNESS GRP (OTC: SARSF ) shares closed up 15.62% at $0.04 GTEC Holdings (OTCQB: GGTTF ) shares closed up 14.2% at $0.72 Zynerba Pharmaceuticals (NASDAQ: ZYNE ) shares closed up 9.94% at $5.31 Corbus Pharmaceuticals (NASDAQ: CRBP ) shares closed up 8.8% at $2.35 Tetra Bio Pharma (OTCQB: TBPMF ) shares closed up 8.02% at $0.16 GrowGeneration (NASDAQ: GRWG ) shares closed up 7.94% at $54.78 High Tide (OTCQB: HITIF ) shares closed up 6.27% … Full story available on

Benzinga | March 19, 2021

Corbus Pharmaceuticals (CRBP) Moves to Buy: Rationale Behind the Upgrade

Corbus Pharmaceuticals (CRBP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Yahoo Finance | March 18, 2021

Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2020 Financial Results

●Phase 3 study of lenabasum in dermatomyositis on schedule for topline data in Q2 2021 ●Company focused on advancing in-house programs in metabolic…

GlobeNewswire | March 15, 2021

Corbus Pharmaceuticals Nothing seems to bother Stock market Insights & financial analysis

Corbus Pharmaceuticals announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…

Stock Market Daily | March 15, 2021

Corbus Pharmaceuticals Holdings, Inc. (CRBP) Q4 2020 Earnings Call Transcript

Image source: The Motley Fool. Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP)Q4 2020 Earnings CallMar 15, 2021, 8:30 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorHello, and welcome to the Corbus Pharmaceuticals Fourth Quarter and Year-End 2020 Earnings Conference Call.

Yahoo | March 15, 2021

Recap: Corbus Pharmaceuticals Q4 Earnings

Shares of Corbus Pharmaceuticals (NASDAQ:CRBP) moved higher by 5.2% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 75.61% year over year to ($0.10), which beat the estimate of ($0.25). Revenue of $658,204 declined by 74.43% year over year, which missed the estimate of $1,490,000. Outlook Earnings guidance hasn't been issued by the company for now. Revenue guidance hasn't been issued by the company for now. Details Of The Call Date: Mar 15, 2021 View more earnings on CRBP Time: 08:30 AM ET Webcast URL: Recent Stock Performance Company's 52-week high was at $9.78 52-week low: $0.91 Price action over last quarter: Up 100.82% Company Overview Cor...

Yahoo | March 15, 2021

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8036 seconds.